Literature DB >> 10619927

PEG-Hemoglobin as a resuscitation solution in the treatment of hypovolemic shock in the anesthetized rat.

C D Conover1, R Linberg, L Lejeune, M Nagy, K L Shum.   

Abstract

This study was designed to determine the advantages of using the hemoglobin-based oxygen carrier, polyethylene glycol conjugated bovine hemoglobin (PEG-Hb), as an additive to Ringer's lactate solution (RLS) for the treatment of acute hemorrhage in anesthetized female rats. Different compositions of PEG-Hb and RLS were administered intravenously in a paradigm that provided 30 ml/kg of resuscitation fluid following an episode of 15 min of hypotension. Hypotension was achieved by the removal of blood (1 ml/min) from the femoral vein until the mean arterial pressure was lowered to or below 50 mmHg and subsequently maintained until resuscitation. Short-term cardiovascular assessment showed that resuscitation fluids containing PEG-Hb resulted in higher mean arterial pressure, aortic blood flow, renal blood flow, and less dramatic shifts in arterial base excess and respiratory blood gases than plain RLS. The long-term survival experiment showed lower lactate dehydrogenase, alkaline phosphatase, and serum glutamic pyruvic transaminase levels in most groups resuscitated with solutions containing PEG-Hb, but no differences in survival (100%) were observed. The data suggest that the addition of PEG-Hb to RLS improves its resuscitative effects. Specifically, a solution of 50% RLS:50% PEG-Hb appeared to have the most favorable cardiovascular and metabolic effects in this anesthetized rat hypovolemic shock resuscitation model. Presumably, the improved effects seen with the addition of PEG-Hb were due to its innate plasma expansion and oxygen-delivery capabilities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619927     DOI: 10.1111/j.1525-1594.1999.06429.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  6 in total

1.  Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism.

Authors:  Paul W Buehler; Jin Hyen Baek; Christina Lisk; Ian Connor; Tim Sullivan; Douglas Kominsky; Susan Majka; Kurt R Stenmark; Eva Nozik-Grayck; Joe Bonaventura; David C Irwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-22       Impact factor: 5.464

2.  Modulation of oxidative stability of haemoglobin inside liposome-encapsulated haemoglobin.

Authors:  Vibhudutta Awasthi; Vivek R Yadav; Beth Goins; William T Phillips
Journal:  J Microencapsul       Date:  2012-12-11       Impact factor: 3.142

3.  Resuscitation with macromolecular superoxide dismutase/catalase mimetic polynitroxylated PEGylated hemoglobin offers neuroprotection in guinea pigs after traumatic brain injury combined with hemorrhage shock.

Authors:  Soichiro Seno; Jun Wang; Suyi Cao; Manda Saraswati; Sharon Park; Jan Simoni; Li Ma; Bohdan Soltys; Carleton J C Hsia; Raymond C Koehler; Courtney L Robertson
Journal:  BMC Neurosci       Date:  2020-05-13       Impact factor: 3.288

4.  High- and low-affinity PEGylated hemoglobin-based oxygen carriers: Differential oxidative stress in a Guinea pig transfusion model.

Authors:  Esra'a Alomari; Luca Ronda; Stefano Bruno; Gianluca Paredi; Marialaura Marchetti; Stefano Bettati; Davide Olivari; Francesca Fumagalli; Deborah Novelli; Giuseppe Ristagno; Roberto Latini; Chris E Cooper; Brandon J Reeder; Andrea Mozzarelli
Journal:  Free Radic Biol Med       Date:  2018-06-18       Impact factor: 7.376

5.  22nd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 19-22 March 2002.

Authors:  Jonathan Ball; Richard Venn; Gareth Williams; Lui Forni
Journal:  Crit Care       Date:  2002-04-30       Impact factor: 9.097

6.  Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute.

Authors:  Risa Haruki; Takuya Kimura; Hitomi Iwasaki; Kana Yamada; Ikuo Kamiyama; Mitsutomo Kohno; Kazuaki Taguchi; Saori Nagao; Toru Maruyama; Masaki Otagiri; Teruyuki Komatsu
Journal:  Sci Rep       Date:  2015-07-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.